Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | Chief of Clinical Operations | March 11, 2026 | March 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TriSalus Life Sciences, Inc.
Report date March 11, 2026 · Filed March 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 97,364 |
Ending reported balance
After 2026-03-16 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-03-11 · Sale · Disposed 1,162 · Balance 99,409 F1: Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person. Row 2 · 2026-03-12 · Sale · Disposed 1,772 · Balance 97,637 F1: Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person. Row 3 · 2026-03-16 · Sale · Disposed 273 · Balance 97,364 F1: Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2026 Filed Mar 20, 2026 16:25 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | SaleCommon Stock | 273 | $4.12 | $1,124.76 |
DisclosureSEC source: 0001628280-26-020190 · wk-form4_1774038352.xml · nonDerivative · entry 3 Devlin Jodi · CIK 0001992151 · Chief of Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,364 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person. Read SEC document |
| March 12, 2026 Filed Mar 20, 2026 16:25 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | SaleCommon Stock | 1,772 | $4.09 | $7,247.48 |
DisclosureSEC source: 0001628280-26-020190 · wk-form4_1774038352.xml · nonDerivative · entry 2 Devlin Jodi · CIK 0001992151 · Chief of Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,637 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person. Read SEC document |
| March 11, 2026 Filed Mar 20, 2026 16:25 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | SaleCommon Stock | 1,162 | $4.13 | $4,799.06 |
DisclosureSEC source: 0001628280-26-020190 · wk-form4_1774038352.xml · nonDerivative · entry 1 Devlin Jodi · CIK 0001992151 · Chief of Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,409 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 15:56 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.55 | $0.00 |
DisclosureSEC source: 0001992151-25-000004 · wk-form4_1764104159.xml · derivative · entry 2 Devlin Jodi · CIK 0001992151 · Chief of Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 463,750 Underlying: Common Stock · 100,000 shares Expires 2025-11-23 F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of November 24, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to continued employment through the respective vesting date. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 15:56 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001992151-25-000004 · wk-form4_1764104159.xml · nonDerivative · entry 1 Devlin Jodi · CIK 0001992151 · Chief of Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,571 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on November 24, 2025, subject to continued employment through the respective vesting date. Read SEC document |
| May 19, 2025 Filed May 21, 2025 17:31 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | SaleCommon Stock | 4,764 | $5.18 | $24,677.52 |
DisclosureSEC source: 0001826667-25-000059 · wk-form4_1747863107.xml · nonDerivative · entry 2 Devlin Jodi · CIK 0001992151 · Chief of Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,764 F2 · shares: The sale of the shares was to cover the tax liability associated with the granted RSUs. Read SEC document |
| May 19, 2025 Filed May 21, 2025 17:31 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 24,131 | $5.18 | $124,998.58 |
DisclosureSEC source: 0001826667-25-000059 · wk-form4_1747863107.xml · nonDerivative · entry 1 Devlin Jodi · CIK 0001992151 · Chief of Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,528 F1 · shares: The granted RSUs vest immediately. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 17:37 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 5,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-004680 · form4-02192025_100231.xml · nonDerivative · entry 1 Devlin Jodi · CIK 0001992151 · Chief of Clinical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,397 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. 12.5% of the shares subject to the RSU Award shall vest on the grant date of February 18, 2025; 25% of the shares subject to the RSU Award shall vest on each of May 15, 2025, August 15, 2025, and November 14, 2025; and the remaining shares subject to the RSU Award will vest on February 13, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 18:00 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 63,750 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001415889-25-002285 · form4-01292025_110128.xml · derivative · entry 2 Devlin Jodi · CIK 0001992151 · Chief of COMMERC. OPERATIONS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,750 Underlying: Common Stock · 63,750 shares Expires 2035-01-26 F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of January 1, 2025 (the "VCD"), and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the VCD (or if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service with the Issuer on each respective vesting date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 18:00 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002285 · form4-01292025_110128.xml · nonDerivative · entry 1 Devlin Jodi · CIK 0001992151 · Chief of COMMERC. OPERATIONS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,125 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on January 1, 2025, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 18:19 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $9.50 | $0.00 |
DisclosureSEC source: 0001415889-24-003807 · form4-02142024_110246.xml · derivative · entry 2 Devlin Jodi · CIK 0001992151 · PRESIDENT, COMMERC. OPERATIONS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2034-02-11 F2 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of February 12, 2024, and 1/36th of the remaining shares shall vest each month thereafter, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 18:19 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003807 · form4-02142024_110246.xml · nonDerivative · entry 1 Devlin Jodi · CIK 0001992151 · PRESIDENT, COMMERC. OPERATIONS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU Award vest in four equal annual installments commencing on February 12, 2024, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 21:04 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantEmployee Stock Option (right to buy) · Derivative | 195,000 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001209191-23-047894 · doc4.xml · derivative · entry 1 Devlin Jodi · CIK 0001992151 · President, Therapeutics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2033-08-29 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of August 28, 2023, and 1/36th of the remaining shares shall vest each month thereafter on the same day of the month as the vesting commencement date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.